Estetrol has DUAL efficacy in the treatment ofend-stage breast cancer
The pregnancy estrogen Estetrol (E4) has a DUAL effect when treating heavily-pre-treated women with advanced breast cancer who have no further treatment options. First, E4 has an anti-tumor effect and second, E4 improves wellbeing.
The Dutch biotech company Pantarhei Oncology presents on December 13, 2019 at the San Antonio Breast Cancer Symposium (SABCS) in the USA the results of the first clinical study with High Doses of the fetal estrogen Estetrol (HDE4) in women with advanced end-stage breast cancer. Nine women without further treatment options participated in the study and were treated with 20, 40 or 60 mg E4 per day for 12 weeks. Anti-tumor effects after 12 weeks treatment were confirmed in 5 of 9 women and strong improvement of wellbeing occurred in 7 of 9 patients.
For more information please read the Press Release or the Poster.
Voor meer informatie lees hier het Nederlandstalig persbericht.